.jpg)
Arcturus confident of retaining BARDA funding for bird flu trial, despite Moderna uncertainty
Arcturus believes it’s “highly unlikely” it will lose the government funding for its mRNA bird flu vaccine trial, despite rumors swirling that Moderna’s funding will be revoked.
Arcturus believes it’s “highly unlikely” it will lose the government funding for its mRNA bird flu vaccine trial, despite rumors swirling that Moderna’s funding will be revoked.
